NCT07640984
A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)
Not Yet Recruiting
PHASE1Up to 5InterventionalTreatmentJCR Pharmaceuticals Co., Ltd.
~12 participants
Updated 2026-07-07 on ClinicalTrials.gov
What's tested:JR-446
At a glance
Recruiting sites
0 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To establish the safety and tolerability of JR-446 in MPS IIIB patients following repeated dose administration
Measured over Up to 1 year (multiple visits)
Conditions
Where it's being run
5 sites across 5 statesCalifornia1
Pennsylvania1
Virginia1
Germany1
United Kingdom1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To establish the safety and tolerability of JR-446 in MPS IIIB patients following repeated dose administrationUp to 1 year (multiple visits)
Incidence and severity of treatment-emergent adverse events; Incidence and severity of infusion-associated reactions; Incidence of clinically significant changes/abnormalities in safety laboratory tests, vital signs, and electrocardiogram.